GlassScriptPhysician profile
Natasha D Wardsworth
NPI 1497115976
$4,620.33
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.84 · 2022: $1,445 · 2023: $2,424 · 2024: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $704.14 | 2022-2023 | Monoferric |
| Daiichi Sankyo INC. | $482.61 | 2023-2024 | Injectafer |
| Apellis Pharmaceuticals, INC. | $440.52 | 2022-2024 | Empaveli |
| Astrazeneca Pharmaceuticals LP | $400.56 | 2022-2024 | Calquence |
| Sobi, INC | $301.99 | 2022-2024 | |
| Pharmaessentia USA Corporation | $237.47 | 2022-2024 | Besremi |
| Incyte Corporation | $234.25 | 2022-2024 | Jakafi |
| Alexion Pharmaceuticals, INC. | $226.32 | 2022-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $205.61 | 2022-2024 | |
| Amgen INC. | $188.87 | 2023 | Nplate, Xgeva, Tavneos |
| Impulse Dynamics (USA) INC. | $158.12 | 2022 | |
| Celgene Corporation | $157.57 | 2022-2024 | Reblozyl, Pomalyst |
| Boston Scientific Corporation | $149.85 | 2022 | |
| Beigene USA, INC. | $141.94 | 2023-2024 | Brukinsa |
| Pfizer INC. | $139.42 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $116.79 | 2022 | |
| Grifols USA, LLC | $56.88 | 2023 | Thrombate III |
| Takeda Pharmaceuticals U.S.A., INC. | $53.85 | 2022 | |
| Rigel Pharmaceuticals, INC. | $50.87 | 2022-2023 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $43.55 | 2022-2023 | Dificid |
| Genzyme Corporation | $31.67 | 2023 | |
| Chiesi USA, INC. | $28.25 | 2022 | |
| Lilly USA, LLC | $24.61 | 2023 | Jaypirca |
| Glaxosmithkline, LLC. | $23.28 | 2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $21.34 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Wardsworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.